-
1
-
-
0347946753
-
Differences between clinical trials and postmarketing use
-
1884419, 14678345
-
Martin K, Bégaud B, Latry P, Miremont-Salamé G, Fourrier A, Moore N. Differences between clinical trials and postmarketing use. Br J Clin Pharmacol 2004, 57:86-92. 1884419, 14678345.
-
(2004)
Br J Clin Pharmacol
, vol.57
, pp. 86-92
-
-
Martin, K.1
Bégaud, B.2
Latry, P.3
Miremont-Salamé, G.4
Fourrier, A.5
Moore, N.6
-
2
-
-
22744434641
-
European Haemophilia Therapy Standardisation Board. Recommendations for postmarketing surveillance studies in haemophilia and other bleeding disorders
-
10.1111/j.1365-2516.2005.01114.x, 16011587
-
Lassila R, Rothschild C, De Moerloose P, Richards M, Perez R, Gajek H. European Haemophilia Therapy Standardisation Board. Recommendations for postmarketing surveillance studies in haemophilia and other bleeding disorders. Haemophilia 2005, 11:353-359. 10.1111/j.1365-2516.2005.01114.x, 16011587.
-
(2005)
Haemophilia
, vol.11
, pp. 353-359
-
-
Lassila, R.1
Rothschild, C.2
De Moerloose, P.3
Richards, M.4
Perez, R.5
Gajek, H.6
-
3
-
-
33646744337
-
Under-reporting of adverse drug reactions: a systematic review
-
10.2165/00002018-200629050-00003, 16689555
-
Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006, 29:385-396. 10.2165/00002018-200629050-00003, 16689555.
-
(2006)
Drug Saf
, vol.29
, pp. 385-396
-
-
Hazell, L.1
Shakir, S.A.W.2
-
4
-
-
77949407113
-
The missing voice of patients in drug-safety reporting
-
10.1056/NEJMp0911494, 3031980, 20220181
-
Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med 2010, 362:865-869. 10.1056/NEJMp0911494, 3031980, 20220181.
-
(2010)
N Engl J Med
, vol.362
, pp. 865-869
-
-
Basch, E.1
-
5
-
-
12444326149
-
Patient-reported medication symptoms in primary care
-
10.1001/archinte.165.2.234, 15668373
-
Weingart SN, Gandhi TK, Seger AC, Seger DL, Borus J, Burdick E, Leape LL, Bates DW. Patient-reported medication symptoms in primary care. Arch Intern Med 2005, 165:234-240. 10.1001/archinte.165.2.234, 15668373.
-
(2005)
Arch Intern Med
, vol.165
, pp. 234-240
-
-
Weingart, S.N.1
Gandhi, T.K.2
Seger, A.C.3
Seger, D.L.4
Borus, J.5
Burdick, E.6
Leape, L.L.7
Bates, D.W.8
-
6
-
-
37749024537
-
Importance of observational studies in clinical practice
-
Spec No, 10.1016/j.clinthera.2007.07.004, 18046928
-
Ligthelm RJ, Borzì V, Gumprecht J, Kawamori R, Wenying Y, Valensi P. Importance of observational studies in clinical practice. Clin Ther 2007, 29:1284-1292. Spec No, 10.1016/j.clinthera.2007.07.004, 18046928.
-
(2007)
Clin Ther
, vol.29
, pp. 1284-1292
-
-
Ligthelm, R.J.1
Borzì, V.2
Gumprecht, J.3
Kawamori, R.4
Wenying, Y.5
Valensi, P.6
-
7
-
-
0031696868
-
Prescription-event monitoring--recent progress and future horizons
-
1873686, 9764958
-
Mann RD. Prescription-event monitoring--recent progress and future horizons. Br J Clin Pharmacol 1998, 46:195-201. 1873686, 9764958.
-
(1998)
Br J Clin Pharmacol
, vol.46
, pp. 195-201
-
-
Mann, R.D.1
-
8
-
-
33644906137
-
Brief communication: Better ways to question patients about adverse medical events: A Randomized, Controlled Trial
-
Bent S, Padula A, Avins AL. Brief communication: Better ways to question patients about adverse medical events: A Randomized, Controlled Trial. Ann Intern Med 2006, 144:257-261.
-
(2006)
Ann Intern Med
, vol.144
, pp. 257-261
-
-
Bent, S.1
Padula, A.2
Avins, A.L.3
-
9
-
-
7044226470
-
Strategies for detecting adverse drug events among older persons in the ambulatory setting
-
10.1197/jamia.M1586, 524629, 15299000
-
Field TS, Gurwitz JH, Harrold LR, Rothschild JM, DeBellis K, Seger AC, Fish LS, Garber L, Kelleher M, Bates DW. Strategies for detecting adverse drug events among older persons in the ambulatory setting. J Am Med Inform Assoc 2004, 11:492-498. 10.1197/jamia.M1586, 524629, 15299000.
-
(2004)
J Am Med Inform Assoc
, vol.11
, pp. 492-498
-
-
Field, T.S.1
Gurwitz, J.H.2
Harrold, L.R.3
Rothschild, J.M.4
DeBellis, K.5
Seger, A.C.6
Fish, L.S.7
Garber, L.8
Kelleher, M.9
Bates, D.W.10
-
10
-
-
80054916474
-
ICH Topic E 2 E Pharmacovigilance Planning (Pvp) Note for guidance on planning pharmacovigilance activities (CPMP/ICH/5716/03) [online]
-
European Medicines Agency Committee for medicinal products for human use (CHMP)
-
European Medicines Agency Committee for medicinal products for human use (CHMP) ICH Topic E 2 E Pharmacovigilance Planning (Pvp) Note for guidance on planning pharmacovigilance activities (CPMP/ICH/5716/03) [online]. 2011, European Medicines Agency Committee for medicinal products for human use (CHMP)., http://www.ema.europa.eu/pdfs/human/ich/571603en.pdf
-
(2011)
-
-
-
11
-
-
80054911814
-
ICH Topic E1 The Extent of Population Exposure to Assess Clinical Safety for Drugs Intended for Long-Term Treatment of Non-Life-Threatening Conditions (CPMP/ICH/375/95) [online]
-
European Medicines Agency Committee for medicinal products for human use (CHMP)
-
European Medicines Agency Committee for medicinal products for human use (CHMP) ICH Topic E1 The Extent of Population Exposure to Assess Clinical Safety for Drugs Intended for Long-Term Treatment of Non-Life-Threatening Conditions (CPMP/ICH/375/95) [online]. 2011, European Medicines Agency Committee for medicinal products for human use (CHMP)., http://www.ema.europa.eu/pdfs/human/ich/037595en.pdf
-
(2011)
-
-
-
12
-
-
80054922388
-
Guidance for Industry. Premarketing Risk Assessment, March 2005 [online]
-
US Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research (CDER)
-
US Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research (CDER) Guidance for Industry. Premarketing Risk Assessment, March 2005 [online]. 2011, US Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research (CDER)., http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126958.pdf
-
(2011)
-
-
-
13
-
-
77954655813
-
ICH Topic E6 (R1) Guideline for Good Clinical Practice (CPMP/ICH/135/95) [online]
-
European Medicines Agency Committee for medicinal products for human use (CHMP)
-
European Medicines Agency Committee for medicinal products for human use (CHMP) ICH Topic E6 (R1) Guideline for Good Clinical Practice (CPMP/ICH/135/95) [online]. 2011, European Medicines Agency Committee for medicinal products for human use (CHMP)., http://www.ema.europa.eu/pdfs/human/ich/013595en.pdf
-
(2011)
-
-
-
14
-
-
4043084862
-
Adverse drug events and medication errors: detection and classification methods
-
10.1136/qshc.2004.010611, 1743868, 15289635
-
Morimoto T, Gandhi TK, Seger AC, Hsieh TC, Bates DW. Adverse drug events and medication errors: detection and classification methods. Qual Saf Health Care 2004, 13:306-314. 10.1136/qshc.2004.010611, 1743868, 15289635.
-
(2004)
Qual Saf Health Care
, vol.13
, pp. 306-314
-
-
Morimoto, T.1
Gandhi, T.K.2
Seger, A.C.3
Hsieh, T.C.4
Bates, D.W.5
-
15
-
-
12344312699
-
Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0, August 9, 2006 [online]
-
National Cancer Institute. Cancer Therapy Evaluation Program
-
National Cancer Institute. Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0, August 9, 2006 [online]. 2011, National Cancer Institute. Cancer Therapy Evaluation Program., http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
-
(2011)
-
-
-
16
-
-
80054883512
-
Guidance for Industry. Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes December, 2008 [online]
-
US Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research (CDER)
-
US Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research (CDER) Guidance for Industry. Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes December, 2008 [online]. 2011, US Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research (CDER)., http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf
-
(2011)
-
-
-
17
-
-
80054908200
-
Guideline on clinical investigation of medicinal products in the treatment of diabetes mellitus. Draft. CPMP/EWP/1080/00 Rev. 1. 20 Jan 2010 [online]
-
European Medicines Agency Committee for medicinal products for human use (CHMP)
-
European Medicines Agency Committee for medicinal products for human use (CHMP) Guideline on clinical investigation of medicinal products in the treatment of diabetes mellitus. Draft. CPMP/EWP/1080/00 Rev. 1. 20 Jan 2010 [online]. 2011, European Medicines Agency Committee for medicinal products for human use (CHMP)., http://www.ema.europa.eu/pdfs/human/ewp/108000enrev1.pdf
-
(2011)
-
-
-
18
-
-
0035186582
-
Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus
-
10.1046/j.1365-2036.2001.00896.x, 11136287
-
Bytzer P, Talley NJ, Jones MP, Horowitz M. Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus. Aliment Pharmacol Ther 2001, 15:137-142. 10.1046/j.1365-2036.2001.00896.x, 11136287.
-
(2001)
Aliment Pharmacol Ther
, vol.15
, pp. 137-142
-
-
Bytzer, P.1
Talley, N.J.2
Jones, M.P.3
Horowitz, M.4
-
19
-
-
35648987622
-
Extent of satisfaction with tablets and food-timing in sulphonylurea-treated diabetes
-
10.1016/j.diabres.2005.07.013, 17517445
-
Woodcock A, Bain S, Charlton M, Bradley C. Extent of satisfaction with tablets and food-timing in sulphonylurea-treated diabetes. Diabetes Res Clin Pract 2007, 78:324-333. 10.1016/j.diabres.2005.07.013, 17517445.
-
(2007)
Diabetes Res Clin Pract
, vol.78
, pp. 324-333
-
-
Woodcock, A.1
Bain, S.2
Charlton, M.3
Bradley, C.4
-
20
-
-
43449094999
-
Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France
-
Vexiau P, Mavros P, Krishnarajah G, Lyu R, Yin D. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. Diabetes Obes Metab 2008, 10(suppl 1):16-24.
-
(2008)
Diabetes Obes Metab
, vol.10
, Issue.SUPPL. 1
, pp. 16-24
-
-
Vexiau, P.1
Mavros, P.2
Krishnarajah, G.3
Lyu, R.4
Yin, D.5
-
21
-
-
33750573488
-
Drug-related problems in patients with angina pectoris, type 2 diabetes and asthma - interviewing patients at home
-
10.1007/s11096-006-9023-9, 17066246
-
Haugbolle LS, Sorensen EW. Drug-related problems in patients with angina pectoris, type 2 diabetes and asthma - interviewing patients at home. Pharm World Sci 2006, 28:239-247. 10.1007/s11096-006-9023-9, 17066246.
-
(2006)
Pharm World Sci
, vol.28
, pp. 239-247
-
-
Haugbolle, L.S.1
Sorensen, E.W.2
-
22
-
-
56549084177
-
Adherence to anti-diabetic drug therapy and self management practices among type-2 diabetics in Nigeria
-
10.1007/s11096-008-9243-2, 18784982
-
Yusuff KB, Obe O, Joseph BY. Adherence to anti-diabetic drug therapy and self management practices among type-2 diabetics in Nigeria. Pharm World Sci 2008, 30:876-883. 10.1007/s11096-008-9243-2, 18784982.
-
(2008)
Pharm World Sci
, vol.30
, pp. 876-883
-
-
Yusuff, K.B.1
Obe, O.2
Joseph, B.Y.3
-
23
-
-
0142105928
-
Effect of add-on acarbose to insulin therapy in routine clinical practice
-
Klocke KR, Stauch K, Landen H. Effect of add-on acarbose to insulin therapy in routine clinical practice. Clin Drug Invest 2003, 23:621-627.
-
(2003)
Clin Drug Invest
, vol.23
, pp. 621-627
-
-
Klocke, K.R.1
Stauch, K.2
Landen, H.3
-
24
-
-
0034151246
-
Does holiday hypoglycaemia exist?
-
Guagnano MT, Pace-Palitti V, Formisano S, Della Loggia F, D'Anchino M, Della Vecchia R, Merlitti D, Sensi S. Does holiday hypoglycaemia exist?. Panminerva Med 2000, 42:23-26.
-
(2000)
Panminerva Med
, vol.42
, pp. 23-26
-
-
Guagnano, M.T.1
Pace-Palitti, V.2
Formisano, S.3
Della Loggia, F.4
D'Anchino, M.5
Della Vecchia, R.6
Merlitti, D.7
Sensi, S.8
-
25
-
-
0033366695
-
Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents
-
10.2337/diacare.22.12.2067, 10587844
-
Jick SS, Stender M, Myers MW. Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents. Diabetes Care 1999, 22:2067-2071. 10.2337/diacare.22.12.2067, 10587844.
-
(1999)
Diabetes Care
, vol.22
, pp. 2067-2071
-
-
Jick, S.S.1
Stender, M.2
Myers, M.W.3
-
26
-
-
34247871323
-
Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration
-
UK Hypoglycaemia Study Group
-
UK Hypoglycaemia Study Group Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007, 50:1140-1147. UK Hypoglycaemia Study Group.
-
(2007)
Diabetologia
, vol.50
, pp. 1140-1147
-
-
-
27
-
-
33645029685
-
Postmarketing study of nateglinide in Japan: treatment of medication-naive patients with type 2 diabetes
-
10.1007/BF02849956, 16510379
-
Taki H, Maki T, Iso T, Tanabe S, Kajiura T. Postmarketing study of nateglinide in Japan: treatment of medication-naive patients with type 2 diabetes. Adv Ther 2005, 22:621-635. 10.1007/BF02849956, 16510379.
-
(2005)
Adv Ther
, vol.22
, pp. 621-635
-
-
Taki, H.1
Maki, T.2
Iso, T.3
Tanabe, S.4
Kajiura, T.5
-
28
-
-
31144458077
-
Postmarketing surveillance study of nateglinide in Japan
-
10.1007/BF02849871, 16418160
-
Taki H, Maki T, Iso T, Iwamoto K, Kajiura T. Postmarketing surveillance study of nateglinide in Japan. Adv Ther 2005, 22:513-526. 10.1007/BF02849871, 16418160.
-
(2005)
Adv Ther
, vol.22
, pp. 513-526
-
-
Taki, H.1
Maki, T.2
Iso, T.3
Iwamoto, K.4
Kajiura, T.5
-
29
-
-
0035115289
-
Troglitazone and liver function abnormalities: lessons from a prescription event monitoring study and spontaneous reporting
-
10.2165/00002018-200124020-00004, 11235818
-
Biswas P, Wilton LV, Shakir SAW. Troglitazone and liver function abnormalities: lessons from a prescription event monitoring study and spontaneous reporting. Drug Saf 2001, 24:149-154. 10.2165/00002018-200124020-00004, 11235818.
-
(2001)
Drug Saf
, vol.24
, pp. 149-154
-
-
Biswas, P.1
Wilton, L.V.2
Shakir, S.A.W.3
-
30
-
-
0033799522
-
Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with Type 2 diabetes
-
Landgraf R, Frank M, Bauer C, Dieken ML. Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with Type 2 diabetes. Int J Obes Relat Metab Disord 2000, 24(suppl 3):S38-44.
-
(2000)
Int J Obes Relat Metab Disord
, vol.24
, Issue.SUPPL. 3
-
-
Landgraf, R.1
Frank, M.2
Bauer, C.3
Dieken, M.L.4
-
31
-
-
33947168360
-
Patient-reported perceptions of side effects of antihyperglycemic medication and adherence to medication regimens in persons with diabetes mellitus
-
10.1016/j.clinthera.2007.01.014, 17379058
-
Chao J, Nau DP, Aikens JE. Patient-reported perceptions of side effects of antihyperglycemic medication and adherence to medication regimens in persons with diabetes mellitus. Clin Ther 2007, 29:177-180. 10.1016/j.clinthera.2007.01.014, 17379058.
-
(2007)
Clin Ther
, vol.29
, pp. 177-180
-
-
Chao, J.1
Nau, D.P.2
Aikens, J.E.3
-
32
-
-
43549097824
-
The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions
-
10.1089/dia.2008.0244, 18473695
-
Karagiannis E, Pfutzner A, Forst T, Lubben G, Roth W, Grabellus M, Flannery M, Schondorf T. The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions. Diabetes Technol Ther 2008, 10:206-212. 10.1089/dia.2008.0244, 18473695.
-
(2008)
Diabetes Technol Ther
, vol.10
, pp. 206-212
-
-
Karagiannis, E.1
Pfutzner, A.2
Forst, T.3
Lubben, G.4
Roth, W.5
Grabellus, M.6
Flannery, M.7
Schondorf, T.8
-
33
-
-
46149094137
-
The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy
-
10.1016/j.ejheart.2008.05.013, 18571471
-
McAlister FA, Eurich DT, Majumdar SR, Johnson JA. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur J Heart Fail 2008, 10:703-708. 10.1016/j.ejheart.2008.05.013, 18571471.
-
(2008)
Eur J Heart Fail
, vol.10
, pp. 703-708
-
-
McAlister, F.A.1
Eurich, D.T.2
Majumdar, S.R.3
Johnson, J.A.4
-
34
-
-
46149094865
-
Clinical experience with exenatide in predominantly Asian and Pacific Islander patients with type 2 diabetes
-
10.1007/s12020-008-9042-5, 18266113
-
Chokrungvaranon N, Chentanez T, Arakaki RF. Clinical experience with exenatide in predominantly Asian and Pacific Islander patients with type 2 diabetes. Endocrine 2007, 32:311-316. 10.1007/s12020-008-9042-5, 18266113.
-
(2007)
Endocrine
, vol.32
, pp. 311-316
-
-
Chokrungvaranon, N.1
Chentanez, T.2
Arakaki, R.F.3
-
35
-
-
46349089552
-
Evaluation of adverse events of oral antihyperglycaemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysis
-
10.2165/00002512-200825070-00006, 18582148
-
Asche CV, McAdam-Marx C, Shane-McWhorter L, Sheng X, Plauschinat CA. Evaluation of adverse events of oral antihyperglycaemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysis. Drugs Aging 2008, 25:611-622. 10.2165/00002512-200825070-00006, 18582148.
-
(2008)
Drugs Aging
, vol.25
, pp. 611-622
-
-
Asche, C.V.1
McAdam-Marx, C.2
Shane-McWhorter, L.3
Sheng, X.4
Plauschinat, C.A.5
-
36
-
-
33745700035
-
Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study
-
10.1185/030079906X112598, 16846554
-
Hanefeld M, Pfutzner A, Forst T, Lubben G. Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study. Curr Med Res Opin 2006, 22:1211-1215. 10.1185/030079906X112598, 16846554.
-
(2006)
Curr Med Res Opin
, vol.22
, pp. 1211-1215
-
-
Hanefeld, M.1
Pfutzner, A.2
Forst, T.3
Lubben, G.4
-
37
-
-
0041333132
-
Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: Comparative subgroup analyses of glycemic control and blood lipid levels
-
Olansky L, Marchetti A, Lau H. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: Comparative subgroup analyses of glycemic control and blood lipid levels. Clin Ther 2003, 25(suppl B):B64-B80.
-
(2003)
Clin Ther
, vol.25 B
, Issue.SUPPL
-
-
Olansky, L.1
Marchetti, A.2
Lau, H.3
-
38
-
-
1942438519
-
Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study
-
10.1185/030079904125003278, 15119994
-
Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin 2004, 20:565-572. 10.1185/030079904125003278, 15119994.
-
(2004)
Curr Med Res Opin
, vol.20
, pp. 565-572
-
-
Blonde, L.1
Dailey, G.E.2
Jabbour, S.A.3
Reasner, C.A.4
Mills, D.J.5
-
39
-
-
11344289613
-
Vitamin B12 status of patients treated with metformin: A cross-sectional cohort study
-
Hermann LS, Nilsson B, Wettre S. Vitamin B12 status of patients treated with metformin: A cross-sectional cohort study. Br J Diabetes Vasc Dis 2004, 4:401-406.
-
(2004)
Br J Diabetes Vasc Dis
, vol.4
, pp. 401-406
-
-
Hermann, L.S.1
Nilsson, B.2
Wettre, S.3
-
40
-
-
35848970300
-
Tolerability of prolonged-release metformin (Glucophage(registered trademark) SR) in individuals intolerant to standard metformin - Results from four UK centres
-
Feher MD, Al-Mrayat M, Brake J, Leong KS. Tolerability of prolonged-release metformin (Glucophage(registered trademark) SR) in individuals intolerant to standard metformin - Results from four UK centres. Br J Diabetes Vasc Dis 2007, 7:225-228.
-
(2007)
Br J Diabetes Vasc Dis
, vol.7
, pp. 225-228
-
-
Feher, M.D.1
Al-Mrayat, M.2
Brake, J.3
Leong, K.S.4
-
41
-
-
9144241091
-
Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital
-
Hussein Z, Wentworth JM, Nankervis AJ, Proietto J, Colman PG. Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital. Med J Aust 2004, 181:536-539.
-
(2004)
Med J Aust
, vol.181
, pp. 536-539
-
-
Hussein, Z.1
Wentworth, J.M.2
Nankervis, A.J.3
Proietto, J.4
Colman, P.G.5
-
42
-
-
33748784333
-
Postmarketing surveillance of acarbose treatment in Taiwanese patients with type 2 diabetes mellitus
-
Hung YJ, Kuo SW, Wang CH, Chang HY, Hsieh SH, Landen H. Postmarketing surveillance of acarbose treatment in Taiwanese patients with type 2 diabetes mellitus. Clin Drug Invest 2006, 26:559-565.
-
(2006)
Clin Drug Invest
, vol.26
, pp. 559-565
-
-
Hung, Y.J.1
Kuo, S.W.2
Wang, C.H.3
Chang, H.Y.4
Hsieh, S.H.5
Landen, H.6
-
43
-
-
36248952778
-
Safety of nateglinide as used in general practice in England: results of a prescription-event monitoring study
-
10.1007/s00592-007-0010-y, 17874223
-
Twaites B, Wilton LV, Layton D, Shakir SAW. Safety of nateglinide as used in general practice in England: results of a prescription-event monitoring study. Acta Diabetol 2007, 44:233-239. 10.1007/s00592-007-0010-y, 17874223.
-
(2007)
Acta Diabetol
, vol.44
, pp. 233-239
-
-
Twaites, B.1
Wilton, L.V.2
Layton, D.3
Shakir, S.A.W.4
-
44
-
-
0033766929
-
Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice
-
Hershon KS, Hershon PM. Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice. Endocrine Practice 2000, 6:20-25.
-
(2000)
Endocrine Practice
, vol.6
, pp. 20-25
-
-
Hershon, K.S.1
Hershon, P.M.2
-
45
-
-
0036808738
-
Comparison of metformin versus sulphonylurea in combination with daily NPH insulin in patients with type 2 diabetes inadequately controlled on oral hypoglycaemic agents: Median follow-up 29 months
-
Furlong NJ, McNulty SJ, O'Brien SV, Hardy KJ. Comparison of metformin versus sulphonylurea in combination with daily NPH insulin in patients with type 2 diabetes inadequately controlled on oral hypoglycaemic agents: Median follow-up 29 months. Pract Diabetes Int 2002, 19:245-249.
-
(2002)
Pract Diabetes Int
, vol.19
, pp. 245-249
-
-
Furlong, N.J.1
McNulty, S.J.2
O'Brien, S.V.3
Hardy, K.J.4
-
46
-
-
43449100355
-
Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study
-
Alvarez Guisasola F, Tofé Povedano S, Krishnarajah G, Lyu R, Mavros P, Yin D. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab 2008, 10(Suppl 1):25-32.
-
(2008)
Diabetes Obes Metab
, vol.10
, Issue.SUPPL. 1
, pp. 25-32
-
-
Alvarez Guisasola, F.1
Tofé Povedano, S.2
Krishnarajah, G.3
Lyu, R.4
Mavros, P.5
Yin, D.6
-
47
-
-
0242332284
-
Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study
-
10.2337/diacare.26.11.2983, 14578227
-
Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 2003, 26:2983-2989. 10.2337/diacare.26.11.2983, 14578227.
-
(2003)
Diabetes Care
, vol.26
, pp. 2983-2989
-
-
Delea, T.E.1
Edelsberg, J.S.2
Hagiwara, M.3
Oster, G.4
Phillips, L.S.5
-
48
-
-
0042425944
-
Efficacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditions
-
Schatz H, Schoppel K, Lehwalder D, Schandry R. Efficacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditions. Exp Clin Endocrinol Diabetes 2003, 111:262-266.
-
(2003)
Exp Clin Endocrinol Diabetes
, vol.111
, pp. 262-266
-
-
Schatz, H.1
Schoppel, K.2
Lehwalder, D.3
Schandry, R.4
-
49
-
-
4644359214
-
Chronic heart failure-related interventions after starting rosiglitazone in patients receiving insulin
-
10.1592/phco.24.14.1317.43155, 15628829
-
Marceille JR, Goins JA, Soni R, Biery JC, Lee TA. Chronic heart failure-related interventions after starting rosiglitazone in patients receiving insulin. Pharmacotherapy 2004, 24:1317-1322. 10.1592/phco.24.14.1317.43155, 15628829.
-
(2004)
Pharmacotherapy
, vol.24
, pp. 1317-1322
-
-
Marceille, J.R.1
Goins, J.A.2
Soni, R.3
Biery, J.C.4
Lee, T.A.5
-
50
-
-
0035998735
-
Lipid response to pioglitazone in diabetic patients: Clinical observations from a retrospective chart review
-
10.1089/15209150260007354, 12079617
-
King AB, Armstrong DU. Lipid response to pioglitazone in diabetic patients: Clinical observations from a retrospective chart review. Diabetes Technol Ther 2002, 4:145-151. 10.1089/15209150260007354, 12079617.
-
(2002)
Diabetes Technol Ther
, vol.4
, pp. 145-151
-
-
King, A.B.1
Armstrong, D.U.2
-
51
-
-
11844290634
-
Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting
-
10.2337/diacare.28.1.20, 15616228
-
Maru S, Koch GG, Stender M, Clark D, Gibowski L, Petri H, White AD, Simpson RJ. Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting. Diabetes Care 2005, 28:20-26. 10.2337/diacare.28.1.20, 15616228.
-
(2005)
Diabetes Care
, vol.28
, pp. 20-26
-
-
Maru, S.1
Koch, G.G.2
Stender, M.3
Clark, D.4
Gibowski, L.5
Petri, H.6
White, A.D.7
Simpson, R.J.8
-
52
-
-
12744255091
-
The incidence of congestive heart failure associated with antidiabetic therapies
-
10.1002/dmrr.480, 15386819
-
Nichols GA, Koro CE, Gullion CM, Ephross SA, Brown JB. The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev 2005, 21:51-57. 10.1002/dmrr.480, 15386819.
-
(2005)
Diabetes Metab Res Rev
, vol.21
, pp. 51-57
-
-
Nichols, G.A.1
Koro, C.E.2
Gullion, C.M.3
Ephross, S.A.4
Brown, J.B.5
-
53
-
-
0034912477
-
Hypoglycemia in patients with type 2 diabetes mellitus
-
10.1001/archinte.161.13.1653, 11434798
-
Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 2001, 161:1653-1659. 10.1001/archinte.161.13.1653, 11434798.
-
(2001)
Arch Intern Med
, vol.161
, pp. 1653-1659
-
-
Miller, C.D.1
Phillips, L.S.2
Ziemer, D.C.3
Gallina, D.L.4
Cook, C.B.5
El-Kebbi, I.M.6
-
54
-
-
19544365090
-
Risk of heart failure with the use of thiazolidinediones within a medicaid population
-
Shaya FT, Shin JY, Mullins CD, El Khoury AC, Garber H. Risk of heart failure with the use of thiazolidinediones within a medicaid population. Pharmacy Therapeutics 2005, 30:273-281.
-
(2005)
Pharmacy Therapeutics
, vol.30
, pp. 273-281
-
-
Shaya, F.T.1
Shin, J.Y.2
Mullins, C.D.3
El Khoury, A.C.4
Garber, H.5
-
55
-
-
0038618808
-
Should we screen diabetic patients using biguanides for megaloblastic anaemia?
-
Filioussi K, Bonovas S, Katsaros T. Should we screen diabetic patients using biguanides for megaloblastic anaemia?. Aust Fam Physician 2003, 32:383-384.
-
(2003)
Aust Fam Physician
, vol.32
, pp. 383-384
-
-
Filioussi, K.1
Bonovas, S.2
Katsaros, T.3
-
56
-
-
0042168813
-
Polypharmacy and medication adherence in patients with type 2 diabetes
-
10.2337/diacare.26.5.1408, 12716797
-
Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care 2003, 26:1408-1412. 10.2337/diacare.26.5.1408, 12716797.
-
(2003)
Diabetes Care
, vol.26
, pp. 1408-1412
-
-
Grant, R.W.1
Devita, N.G.2
Singer, D.E.3
Meigs, J.B.4
-
57
-
-
21344452562
-
Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes
-
10.1111/j.1572-0241.2005.41690.x, 15929763
-
Chalasani N, Teal E, Hall SD. Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes. Am J Gastroenterol 2005, 100:1317-1321. 10.1111/j.1572-0241.2005.41690.x, 15929763.
-
(2005)
Am J Gastroenterol
, vol.100
, pp. 1317-1321
-
-
Chalasani, N.1
Teal, E.2
Hall, S.D.3
-
58
-
-
0031920237
-
Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report
-
10.1136/jamia.1998.0050305, 61304, 9609500
-
Jha AK, Kuperman GJ, Teich JM, Leape L, Shea B, Rittenberg E, Burdick E, Seger DL, Vander Vliet M, Bates DW. Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report. J Am Med Inform Assoc 1998, 5:305-314. 10.1136/jamia.1998.0050305, 61304, 9609500.
-
(1998)
J Am Med Inform Assoc
, vol.5
, pp. 305-314
-
-
Jha, A.K.1
Kuperman, G.J.2
Teich, J.M.3
Leape, L.4
Shea, B.5
Rittenberg, E.6
Burdick, E.7
Seger, D.L.8
Vander Vliet, M.9
Bates, D.W.10
-
59
-
-
2442433545
-
Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting
-
Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med 2004, 140:795-801.
-
(2004)
Ann Intern Med
, vol.140
, pp. 795-801
-
-
Nebeker, J.R.1
Barach, P.2
Samore, M.H.3
-
60
-
-
49549097900
-
Agreement between patient-reported symptoms and their documentation in the medical record
-
2581509, 18690769
-
Pakhomov SV, Jacobsen SJ, Chute CG, Roger VL. Agreement between patient-reported symptoms and their documentation in the medical record. Am J Manag Care 2008, 14:530-539. 2581509, 18690769.
-
(2008)
Am J Manag Care
, vol.14
, pp. 530-539
-
-
Pakhomov, S.V.1
Jacobsen, S.J.2
Chute, C.G.3
Roger, V.L.4
-
61
-
-
0035118454
-
A computerized method for identifying incidents associated with adverse drug events in outpatients
-
10.1016/S1386-5056(00)00131-3, 11248601
-
Honigman B, Light P, Pulling RM, Bates DW. A computerized method for identifying incidents associated with adverse drug events in outpatients. Int J Med Inform 2001, 61:21-32. 10.1016/S1386-5056(00)00131-3, 11248601.
-
(2001)
Int J Med Inform
, vol.61
, pp. 21-32
-
-
Honigman, B.1
Light, P.2
Pulling, R.M.3
Bates, D.W.4
-
62
-
-
34548058076
-
Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance
-
10.2165/00002018-200730080-00003, 17696579
-
Golomb BA, McGraw JJ, Evans MA, Dimsdale JE. Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance. Drug Saf 2007, 30:669-675. 10.2165/00002018-200730080-00003, 17696579.
-
(2007)
Drug Saf
, vol.30
, pp. 669-675
-
-
Golomb, B.A.1
McGraw, J.J.2
Evans, M.A.3
Dimsdale, J.E.4
-
63
-
-
4444327078
-
How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30
-
10.1200/JCO.2004.03.025, 15337796
-
Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol 2004, 22:3485-3490. 10.1200/JCO.2004.03.025, 15337796.
-
(2004)
J Clin Oncol
, vol.22
, pp. 3485-3490
-
-
Fromme, E.K.1
Eilers, K.M.2
Mori, M.3
Hsieh, Y.C.4
Beer, T.M.5
-
65
-
-
3543114278
-
Patients' role in reporting adverse drug reactions
-
10.1517/14740338.3.4.363, 15268652
-
Van Grootheest K, de Jong-van den Berg LT. Patients' role in reporting adverse drug reactions. Expert Opin Drug Saf 2004, 3:363-368. 10.1517/14740338.3.4.363, 15268652.
-
(2004)
Expert Opin Drug Saf
, vol.3
, pp. 363-368
-
-
Van Grootheest, K.1
de Jong-van den Berg, L.T.2
-
66
-
-
65249092106
-
Adverse drug reaction monitoring: comparing doctor and patient reporting for new drugs
-
10.1002/pds.1708, 19148880
-
Jarernsiripornkul N, Kakaew W, Loalukkana W, Krska J. Adverse drug reaction monitoring: comparing doctor and patient reporting for new drugs. Pharmacoepidemiol Drug Saf 2009, 18:240-245. 10.1002/pds.1708, 19148880.
-
(2009)
Pharmacoepidemiol Drug Saf
, vol.18
, pp. 240-245
-
-
Jarernsiripornkul, N.1
Kakaew, W.2
Loalukkana, W.3
Krska, J.4
-
67
-
-
0023801514
-
Patients as a direct source of information on adverse drug reactions
-
10.1136/bmj.297.6653.891, 1834468, 3140967
-
Mitchell AS, Henry DA, Sanson-Fisher R, O'Connell DL. Patients as a direct source of information on adverse drug reactions. BMJ 1988, 297:891-893. 10.1136/bmj.297.6653.891, 1834468, 3140967.
-
(1988)
BMJ
, vol.297
, pp. 891-893
-
-
Mitchell, A.S.1
Henry, D.A.2
Sanson-Fisher, R.3
O'Connell, D.L.4
-
68
-
-
67650531870
-
Focus on headache as an adverse reaction to drugs
-
10.1007/s10194-009-0127-1, 19495934
-
Ferrari A, Spaccapelo L, Gallesi D, Sternieri E. Focus on headache as an adverse reaction to drugs. J Headache Pain 2009, 10:235-239. 10.1007/s10194-009-0127-1, 19495934.
-
(2009)
J Headache Pain
, vol.10
, pp. 235-239
-
-
Ferrari, A.1
Spaccapelo, L.2
Gallesi, D.3
Sternieri, E.4
-
69
-
-
70349970392
-
Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006
-
10.2165/11316680-000000000-00000, 19810778
-
Aagaard L, Nielsen LH, Hansen EH. Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006. Drug Saf 2009, 32:1067-1074. 10.2165/11316680-000000000-00000, 19810778.
-
(2009)
Drug Saf
, vol.32
, pp. 1067-1074
-
-
Aagaard, L.1
Nielsen, L.H.2
Hansen, E.H.3
-
70
-
-
0036120858
-
Patient reporting of potential adverse drug reactions: a methodological study
-
10.1046/j.0306-5251.2001.01547.x, 1874308, 11874396
-
Jarernsiripornkul N, Krska J, Capps PA, Richards RM, Lee A. Patient reporting of potential adverse drug reactions: a methodological study. Br J Clin Pharmacol 2002, 53:318-325. 10.1046/j.0306-5251.2001.01547.x, 1874308, 11874396.
-
(2002)
Br J Clin Pharmacol
, vol.53
, pp. 318-325
-
-
Jarernsiripornkul, N.1
Krska, J.2
Capps, P.A.3
Richards, R.M.4
Lee, A.5
-
71
-
-
40949108913
-
The use of questionnaires for measuring patient-reported side effects of drugs: its importance and methodological challenges
-
10.1002/pds.1533, 18300325
-
Foster JM, van der Molen T, Caeser M, Hannaford P. The use of questionnaires for measuring patient-reported side effects of drugs: its importance and methodological challenges. Pharmacoepidemiol Drug Saf 2008, 17:278-296. 10.1002/pds.1533, 18300325.
-
(2008)
Pharmacoepidemiol Drug Saf
, vol.17
, pp. 278-296
-
-
Foster, J.M.1
van der Molen, T.2
Caeser, M.3
Hannaford, P.4
-
72
-
-
33846521254
-
Linking laboratory and medication data: new opportunities for pharmacoepidemiological research
-
10.1515/CCLM.2007.009, 17243908
-
Ten Berg MJ, Huisman A, van den Bemt PM, Schobben AF, Egberts AC, van Solinge WW. Linking laboratory and medication data: new opportunities for pharmacoepidemiological research. Clin Chem Lab Med 2007, 45:13-19. 10.1515/CCLM.2007.009, 17243908.
-
(2007)
Clin Chem Lab Med
, vol.45
, pp. 13-19
-
-
Ten Berg, M.J.1
Huisman, A.2
van den Bemt, P.M.3
Schobben, A.F.4
Egberts, A.C.5
van Solinge, W.W.6
-
73
-
-
0035002881
-
Using computerized data to identify adverse drug events in outpatients
-
10.1136/jamia.2001.0080254, 131033, 11320070
-
Honigman B, Lee J, Rothschild J, Light P, Pulling RM, Yu T, Bates DW. Using computerized data to identify adverse drug events in outpatients. J Am Med Inform Assoc 2001, 8:254-266. 10.1136/jamia.2001.0080254, 131033, 11320070.
-
(2001)
J Am Med Inform Assoc
, vol.8
, pp. 254-266
-
-
Honigman, B.1
Lee, J.2
Rothschild, J.3
Light, P.4
Pulling, R.M.5
Yu, T.6
Bates, D.W.7
-
74
-
-
53249132632
-
Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma
-
10.1038/nrd2664, 18787530
-
Eichler HG, Pignatti F, Flamion B, Leufkens H, Breckenridge A. Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma. Nat Rev Drug Discov 2008, 7:818-826. 10.1038/nrd2664, 18787530.
-
(2008)
Nat Rev Drug Discov
, vol.7
, pp. 818-826
-
-
Eichler, H.G.1
Pignatti, F.2
Flamion, B.3
Leufkens, H.4
Breckenridge, A.5
-
75
-
-
0029838837
-
Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals
-
2351951, 8789980
-
Egberts TC, Smulders M, de Koning FH, Meyboom RH, Leufkens HG. Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals. BMJ 1996, 313:530-531. 2351951, 8789980.
-
(1996)
BMJ
, vol.313
, pp. 530-531
-
-
Egberts, T.C.1
Smulders, M.2
de Koning, F.H.3
Meyboom, R.H.4
Leufkens, H.G.5
-
76
-
-
33646140576
-
Developing efficient search strategies to identify reports of adverse effects in MEDLINE and EMBASE
-
Centre for Reviews and Dissemination and UK Cochrane Centre Search Filters Design Group
-
Golder S, McIntosh HM, Duffy S, Glanville J, . Centre for Reviews and Dissemination and UK Cochrane Centre Search Filters Design Group Developing efficient search strategies to identify reports of adverse effects in MEDLINE and EMBASE. Health Info Libr J 2006, 23:3-12. Centre for Reviews and Dissemination and UK Cochrane Centre Search Filters Design Group.
-
(2006)
Health Info Libr J
, vol.23
, pp. 3-12
-
-
Golder, S.1
McIntosh, H.M.2
Duffy, S.3
Glanville, J.4
-
77
-
-
4844229862
-
Assessing harmful effects in systematic reviews
-
10.1186/1471-2288-4-19, 497041, 15260887
-
McIntosh HM, Woolacott NF, Bagnall AM. Assessing harmful effects in systematic reviews. BMC Med Res Methodol 2004, 4:19. 10.1186/1471-2288-4-19, 497041, 15260887.
-
(2004)
BMC Med Res Methodol
, vol.4
, pp. 19
-
-
McIntosh, H.M.1
Woolacott, N.F.2
Bagnall, A.M.3
-
78
-
-
41749104203
-
Effectiveness of the novel anti-diabetes medication exenatide in everyday practice: Comparison with clinical trials
-
Donekal S, Shomali ME. Effectiveness of the novel anti-diabetes medication exenatide in everyday practice: Comparison with clinical trials. Diabetes Res Clin Pract 2008, 80:e4-e6.
-
(2008)
Diabetes Res Clin Pract
, vol.80
-
-
Donekal, S.1
Shomali, M.E.2
-
79
-
-
32244433103
-
Follow-up of the use of metformin among the high risk population
-
10.1016/S1130-6343(05)73697-7, 16433568
-
Redondo-Capafons S, Garriga Biosca MR, Pla Poblador R. Follow-up of the use of metformin among the high risk population. Farm Hosp 2005, 29:364-366. 10.1016/S1130-6343(05)73697-7, 16433568.
-
(2005)
Farm Hosp
, vol.29
, pp. 364-366
-
-
Redondo-Capafons, S.1
Garriga Biosca, M.R.2
Pla Poblador, R.3
-
80
-
-
2942668406
-
Conversion from troglitazone to rosiglitazone or pioglitazone in the VA: A multicenter DUE
-
Burk M, Morreale AP, Cunningham F. Conversion from troglitazone to rosiglitazone or pioglitazone in the VA: A multicenter DUE. Formulary 2004, 39:310-317.
-
(2004)
Formulary
, vol.39
, pp. 310-317
-
-
Burk, M.1
Morreale, A.P.2
Cunningham, F.3
-
81
-
-
0037705723
-
Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis
-
10.1592/phco.23.7.861.32727, 12885099
-
Manley HJ, Allcock NM. Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis. Pharmacotherapy 2003, 23:861-865. 10.1592/phco.23.7.861.32727, 12885099.
-
(2003)
Pharmacotherapy
, vol.23
, pp. 861-865
-
-
Manley, H.J.1
Allcock, N.M.2
-
82
-
-
0032918959
-
Safety and efficacy of metformin in a restricted formulary
-
Swislocki AL, Khuu Q, Liao E, Wu E, Beza F, Lopez J, Kwan G, Noth RH. Safety and efficacy of metformin in a restricted formulary. Am J Manag Care 1999, 5:62-68.
-
(1999)
Am J Manag Care
, vol.5
, pp. 62-68
-
-
Swislocki, A.L.1
Khuu, Q.2
Liao, E.3
Wu, E.4
Beza, F.5
Lopez, J.6
Kwan, G.7
Noth, R.H.8
-
83
-
-
0037393015
-
Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure
-
Tang WH, Francis GS, Hoogwerf BJ, Young JB. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. Am Coll Cardiol 2003, 41:1394-1398.
-
(2003)
Am Coll Cardiol
, vol.41
, pp. 1394-1398
-
-
Tang, W.H.1
Francis, G.S.2
Hoogwerf, B.J.3
Young, J.B.4
-
84
-
-
14144253223
-
The alpha-glucosidase inhibitor miglitol for the treatment of type 2 diabetes mellitus in the doctor's office
-
[in German]
-
Fehmann HC. The alpha-glucosidase inhibitor miglitol for the treatment of type 2 diabetes mellitus in the doctor's office. MMW Fortschr Med 2001, 119(Suppl 2):55-61. [in German].
-
(2001)
MMW Fortschr Med
, vol.119
, Issue.SUPPL. 2
, pp. 55-61
-
-
Fehmann, H.C.1
-
85
-
-
3242891451
-
Substitution of pioglitazone for troglitazone in patients with type 2 diabetes
-
Kane MP, Busch RS, Bakst G, Hamilton RA. Substitution of pioglitazone for troglitazone in patients with type 2 diabetes. Endocr Pract 2004, 10:18-23.
-
(2004)
Endocr Pract
, vol.10
, pp. 18-23
-
-
Kane, M.P.1
Busch, R.S.2
Bakst, G.3
Hamilton, R.A.4
-
86
-
-
33947107876
-
Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: postmarketing surveillance study in Japan
-
10.1016/j.diabres.2006.08.017, 17109986, on behalf of the PRACTICAL Study Group
-
Kawamori R, Kadowaki T, Onji M, Seino Y, Akanuma Y, . on behalf of the PRACTICAL Study Group Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: postmarketing surveillance study in Japan. Diabetes Res Clin Pract 2007, 76:229-235. 10.1016/j.diabres.2006.08.017, 17109986, on behalf of the PRACTICAL Study Group.
-
(2007)
Diabetes Res Clin Pract
, vol.76
, pp. 229-235
-
-
Kawamori, R.1
Kadowaki, T.2
Onji, M.3
Seino, Y.4
Akanuma, Y.5
-
87
-
-
0035030824
-
Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study
-
10.1016/S0168-8227(01)00221-2, 11323089
-
Mertes G. Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study. Diabetes Res Clin Pract 2001, 52:193-204. 10.1016/S0168-8227(01)00221-2, 11323089.
-
(2001)
Diabetes Res Clin Pract
, vol.52
, pp. 193-204
-
-
Mertes, G.1
-
88
-
-
34249898882
-
Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China
-
Pan CY, Landen H. Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China. Clin Drug Invest 2007, 27:397-405.
-
(2007)
Clin Drug Invest
, vol.27
, pp. 397-405
-
-
Pan, C.Y.1
Landen, H.2
-
89
-
-
33644848645
-
Rosiglitazone plus metformin is effective and well tolerated in clinical practice: results from large observational studies in people with type 2 diabetes
-
10.1111/j.1368-5031.2005.00652.x, 16178978
-
Rosak C, Petzoldt R, Wolf R, Reblin T, Dehmel B, Seidel D. Rosiglitazone plus metformin is effective and well tolerated in clinical practice: results from large observational studies in people with type 2 diabetes. Int J Clin Pract 2005, 59:1131-1136. 10.1111/j.1368-5031.2005.00652.x, 16178978.
-
(2005)
Int J Clin Pract
, vol.59
, pp. 1131-1136
-
-
Rosak, C.1
Petzoldt, R.2
Wolf, R.3
Reblin, T.4
Dehmel, B.5
Seidel, D.6
-
90
-
-
0034774367
-
Efficacy and tolerability of glimepiride in daily practice: A non-interventional observational cohort study
-
Scholz GH, Schneider K, Knirsch W, Becker G. Efficacy and tolerability of glimepiride in daily practice: A non-interventional observational cohort study. Clin Drug Invest 2001, 21:597-604.
-
(2001)
Clin Drug Invest
, vol.21
, pp. 597-604
-
-
Scholz, G.H.1
Schneider, K.2
Knirsch, W.3
Becker, G.4
-
91
-
-
41549132570
-
One-year follow-up in real clinical practice conditions of type 2 diabetic patients treated with rosiglitazone: the Avantage study
-
[in French], pour le groupe des investigateurs de l'étude Avantage
-
Slama G, Eschwège E, Bernard MH, Grimaldi A, Oppert JM, Pouchain D, Bégaud B, . pour le groupe des investigateurs de l'étude Avantage One-year follow-up in real clinical practice conditions of type 2 diabetic patients treated with rosiglitazone: the Avantage study. Ann Endocrinol 2008, 69:36-46. [in French], pour le groupe des investigateurs de l'étude Avantage.
-
(2008)
Ann Endocrinol
, vol.69
, pp. 36-46
-
-
Slama, G.1
Eschwège, E.2
Bernard, M.H.3
Grimaldi, A.4
Oppert, J.M.5
Pouchain, D.6
Bégaud, B.7
-
92
-
-
24944497145
-
Evaluation of the efficacy and tolerability of acarbose in patients with diabetes mellitus a postmarketing surveillance study
-
Spengler M, Schmitz H, Landen H. Evaluation of the efficacy and tolerability of acarbose in patients with diabetes mellitus a postmarketing surveillance study. Clin Drug Invest 2005, 25:651-659.
-
(2005)
Clin Drug Invest
, vol.25
, pp. 651-659
-
-
Spengler, M.1
Schmitz, H.2
Landen, H.3
-
93
-
-
50649121372
-
Monitoring the safety of pioglitazone: Results of a prescription-event monitoring study of 12 772 patients in England
-
10.2165/00002018-200831100-00003, 18759508
-
Kasliwal R, Wilton LV, Shakir SAW. Monitoring the safety of pioglitazone: Results of a prescription-event monitoring study of 12 772 patients in England. Drug Saf 2008, 31:839-850. 10.2165/00002018-200831100-00003, 18759508.
-
(2008)
Drug Saf
, vol.31
, pp. 839-850
-
-
Kasliwal, R.1
Wilton, L.V.2
Shakir, S.A.W.3
-
94
-
-
0035230314
-
Pilot study of prescription-event monitoring in Japan comparing troglitazone with alternative oral hypoglycemics
-
Kubota K, Kawabe E, Hinotsu S, Hamada C, Ohashi Y, Kurokawa K. Pilot study of prescription-event monitoring in Japan comparing troglitazone with alternative oral hypoglycemics. Eur J Clin Pharmacol 2000, 56:831-838.
-
(2000)
Eur J Clin Pharmacol
, vol.56
, pp. 831-838
-
-
Kubota, K.1
Kawabe, E.2
Hinotsu, S.3
Hamada, C.4
Ohashi, Y.5
Kurokawa, K.6
-
95
-
-
33646881956
-
Safety profile of repaglinide as used in general practice in England: results of a prescription-event monitoring study
-
10.1007/s00592-006-0203-9, 16710643
-
Marshall V, Wilton L, Shakir SAW. Safety profile of repaglinide as used in general practice in England: results of a prescription-event monitoring study. Acta Diabetol 2006, 43:6-13. 10.1007/s00592-006-0203-9, 16710643.
-
(2006)
Acta Diabetol
, vol.43
, pp. 6-13
-
-
Marshall, V.1
Wilton, L.2
Shakir, S.A.W.3
-
96
-
-
45949085098
-
A comparison of select cardiovascular outcomes by antidiabetic prescription drug classes used to treat type 2 diabetes among Military Health System beneficiaries, fiscal year 2003-2006
-
10.1097/MJT.0b013e31817534d5, 18496256
-
Casscells SW, Granger E, Swedorske J, Goldhammer R, Shaheen M, Dorris J, Hong A, Wiktor M. A comparison of select cardiovascular outcomes by antidiabetic prescription drug classes used to treat type 2 diabetes among Military Health System beneficiaries, fiscal year 2003-2006. Am J Ther 2008, 15:198-205. 10.1097/MJT.0b013e31817534d5, 18496256.
-
(2008)
Am J Ther
, vol.15
, pp. 198-205
-
-
Casscells, S.W.1
Granger, E.2
Swedorske, J.3
Goldhammer, R.4
Shaheen, M.5
Dorris, J.6
Hong, A.7
Wiktor, M.8
-
97
-
-
14844356009
-
Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone
-
10.1111/j.1463-1326.2004.00382.x, 15715889
-
Rajagopalan R, Iyer S, Perez A. Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone. Diabetes Obes Metab 2005, 7:161-169. 10.1111/j.1463-1326.2004.00382.x, 15715889.
-
(2005)
Diabetes Obes Metab
, vol.7
, pp. 161-169
-
-
Rajagopalan, R.1
Iyer, S.2
Perez, A.3
-
98
-
-
0344406225
-
Drug-induced renal function impairment: a population-based survey
-
10.1002/pds.811, 12642977
-
Monster TB, de Jong PE, de Jong-van den Berg LT. Drug-induced renal function impairment: a population-based survey. Pharmacoepidemiol Drug Saf 2003, 12:135-143. 10.1002/pds.811, 12642977.
-
(2003)
Pharmacoepidemiol Drug Saf
, vol.12
, pp. 135-143
-
-
Monster, T.B.1
de Jong, P.E.2
de Jong-van den Berg, L.T.3
-
99
-
-
0034332118
-
Metformin-induced lacticacidemia in patients with type 2 diabetes mellitus
-
Abbasi AA, Kasmikha R, Sotingeanu DG. Metformin-induced lacticacidemia in patients with type 2 diabetes mellitus. Endocr Pract 2000, 6:442-446.
-
(2000)
Endocr Pract
, vol.6
, pp. 442-446
-
-
Abbasi, A.A.1
Kasmikha, R.2
Sotingeanu, D.G.3
-
100
-
-
0034232349
-
Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control
-
Gavin LA, Barth J, Arnold D, Shaw R. Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control. Endocr Pract 2000, 6:305-310.
-
(2000)
Endocr Pract
, vol.6
, pp. 305-310
-
-
Gavin, L.A.1
Barth, J.2
Arnold, D.3
Shaw, R.4
-
101
-
-
33745036562
-
Study of nateglinide in Japan: long-term treatment of patients with type 2 diabetes
-
10.1007/BF02850136, 16751163
-
Taki H, Maki T, Iso T, Iwamoto K, Kajiura T. Study of nateglinide in Japan: long-term treatment of patients with type 2 diabetes. Adv Ther 2006, 23:307-324. 10.1007/BF02850136, 16751163.
-
(2006)
Adv Ther
, vol.23
, pp. 307-324
-
-
Taki, H.1
Maki, T.2
Iso, T.3
Iwamoto, K.4
Kajiura, T.5
|